ADMA BIOLOGICS, INC. (ADMA) Form 10-K Annual Reports
ADMA BIOLOGICS, INC. (ADMA) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ADMA
CIK: 1368514
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
KPMG LLP
Auditor SinceSince 12/31/2024 12:00:00 AM
Lead Engagement PartnerJoseph Zeni
Audit LocationStamford, Connecticut, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13G | 2026-08-07 | — | SCHEDULE 13G Filing | 0000093751-26-000402 | View SEC Doc Filr Page |
| 10-Q | 2026-08-05 | 2026-06-30 | 10-Q | 0001140361-26-031445 | View SEC Doc Filr Page |
| 8-K | 2026-08-05 | 2026-08-05 | 8-K | 0001140361-26-031423 | View SEC Doc Filr Page |
| 4 | 2026-07-28 | 2026-07-24 | FORM 4 | 0001140361-26-029923 | View SEC Doc Filr Page |
| 4 | 2026-07-17 | 2026-07-16 | FORM 4 | 0001140361-26-028844 | View SEC Doc Filr Page |
| 8-K | 2026-06-02 | 2026-06-02 | 8-K | 0001140361-26-023705 | View SEC Doc Filr Page |
| 4 | 2026-05-28 | 2026-05-27 | FORM 4 | 0001140361-26-023127 | View SEC Doc Filr Page |
| 4 | 2026-05-14 | 2026-05-12 | FORM 4 | 0001140361-26-021150 | View SEC Doc Filr Page |
| 4 | 2026-05-12 | 2026-05-11 | FORM 4 | 0001140361-26-020855 | View SEC Doc Filr Page |
| 10-Q | 2026-05-06 | 2026-03-31 | 10-Q | 0001140361-26-019336 | View SEC Doc Filr Page |
| 8-K | 2026-05-06 | 2026-05-06 | 8-K | 0001140361-26-019295 | View SEC Doc Filr Page |
| 8-K | 2026-05-04 | 2026-05-04 | 8-K | 0001140361-26-018667 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-04-29 | — | SCHEDULE 13G Filing | 0002100119-26-000078 | View SEC Doc Filr Page |
| ARS | 2026-04-15 | 2025-12-31 | ARS | 0001140361-26-014803 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-15 | — | DEFA14A | 0001140361-26-014801 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-15 | 2026-06-02 | DEF 14A | 0001140361-26-014799 | View SEC Doc Filr Page |
| 4 | 2026-04-03 | 2026-04-01 | FORM 4 | 0001140361-26-013206 | View SEC Doc Filr Page |
| 8-K | 2026-03-27 | 2026-03-27 | 8-K | 0001140361-26-011569 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-03-26 | — | SCHEDULE 13G/A Filing | 0000102909-26-000527 | View SEC Doc Filr Page |
| 4 | 2026-03-17 | 2026-03-13 | FORM 4 | 0001140361-26-009900 | View SEC Doc Filr Page |
| 4 | 2026-03-17 | 2026-03-16 | FROM 4 | 0001140361-26-009899 | View SEC Doc Filr Page |
| 144 | 2026-03-10 | — | 144 Filing | 0001140361-26-008913 | View SEC Doc Filr Page |
| 4 | 2026-03-10 | 2026-03-06 | FORM 4 | 0001140361-26-008905 | View SEC Doc Filr Page |
| 4 | 2026-03-10 | 2026-03-06 | FORM 4 | 0001140361-26-008904 | View SEC Doc Filr Page |
| 144 | 2026-03-09 | — | 144 Filing | 0001140361-26-008523 | View SEC Doc Filr Page |